{"type":"trials","record":{"id":41925,"source_id":"clinicaltrials-gov","external_id":"NCT05112835","title":"Brolucizumab Treatment Experience Study of Patients With nAMD in UK Routine Clinical Practice","brief_summary":"BESRA is a national, multi-center, prospective, observational study to assess the effectiveness of brolucizumab intravitreal injections in patients with nAMD treated in the UK.","overall_status":"Terminated","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Novartis Pharmaceuticals","enrollment":302,"countries":["United Kingdom"],"start_date":"2021-11-19","completion_date":"2022-09-08","last_update_date":"2024-10-29","source_url":"https://clinicaltrials.gov/study/NCT05112835","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"BESRA","age_range":"50 Years","comparator":null,"organization":"Novartis","interventions":["brolucizumab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Percentage (%) of patients with absence of retinal fluid — Month 12","Percentage (%) of patients with absence of SRF — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of IRF — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of sub-RPE fluid — Month 3, month 6, month 12, month 24, month 36, month 48 and…","Percentage (%) of patients with absence of PED — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of retinal fluid — Month 3, month 6, month 12, month 24, month 36, month 48 and…","CRT change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","CST change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","BCVA change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with BCVA ≥70 ETDRS letters — Month 3, month 6, month 12, month 24, month 36, month 48 and m…","Total number of injections received — Up to 60 months","Duration of injection intervals per patient — Up to 60 months","Percentage (%) of patients with ≥3 brolucizumab injections — Month 3","Percentage (%) of patients who switch from brolucizumab to another anti-VEGF — Month 12, month 24, month 36, month 48 a…","Percentage (%) of patients that discontinue Brolucizumab therapy — Up to 60 months","Percentage (%) of patients with IOI including RV and RVO — Up to 60 months","Percentage (%) of patients with disease control — Month 12 and month 24","Change in macular volume of IRF/SRF by central reading center — Baseline at Month 12"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","brolucizumab"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05112835","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-11-19 to 2022-09-08","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.892Z","intervention":["brolucizumab"],"participants":302,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Percentage (%) of patients with absence of retinal fluid — Month 12","Percentage (%) of patients with absence of SRF — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of IRF — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of sub-RPE fluid — Month 3, month 6, month 12, month 24, month 36, month 48 and…","Percentage (%) of patients with absence of PED — Month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with absence of retinal fluid — Month 3, month 6, month 12, month 24, month 36, month 48 and…","CRT change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","CST change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","BCVA change from baseline — Baseline, month 3, month 6, month 12, month 24, month 36, month 48 and month 60","Percentage (%) of patients with BCVA ≥70 ETDRS letters — Month 3, month 6, month 12, month 24, month 36, month 48 and m…","Total number of injections received — Up to 60 months","Duration of injection intervals per patient — Up to 60 months","Percentage (%) of patients with ≥3 brolucizumab injections — Month 3","Percentage (%) of patients who switch from brolucizumab to another anti-VEGF — Month 12, month 24, month 36, month 48 a…","Percentage (%) of patients that discontinue Brolucizumab therapy — Up to 60 months","Percentage (%) of patients with IOI including RV and RVO — Up to 60 months","Percentage (%) of patients with disease control — Month 12 and month 24","Change in macular volume of IRF/SRF by central reading center — Baseline at Month 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41925","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}